FDA hur­ries up a quick ap­proval for the world's first TCR — af­ter a 14-year R&D trek

Over the 14 years since Im­muno­core was spun out of Medi­Gene in a quest to de­vel­op a gamechang­ing can­cer med, the biotech has raised record sums and un­der­gone a ma­jor shake­up on a long roller coast­er ride of val­u­a­tions for in­vestors. But they sur­vived and thrived and to­day they’re pop­ping the cham­pagne corks to cel­e­brate an FDA ap­proval of their first TCR drug.

Im­muno­core flagged the FDA’s green light for tebenta­fusp Wednes­day morn­ing by high­light­ing a se­ries of firsts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER